Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03686124 · ClinicalTrials.gov registry record · Phase 1

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

A Phase 1 study of Cancer and Solid Tumor, Adult, sponsored by Immatics US.

Recruiting
Registry status
Phase 1
Development phase
375
Enrollment target
18
Study locations

NCT03686124 is a Phase 1 study of Cancer and Solid Tumor, Adult that is actively recruiting participants, run by Immatics US. The registered enrollment target is 375 participants, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The trial reports 18 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03686124, a Phase 1 study of Cancer and Solid Tumor, Adult, is actively recruiting participants, sponsored by Immatics US.

RECRUITING
Registry status
Phase 1
Development phase
375 participants
Enrollment target
18
Study locations

Study Summary

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

Conditions Studied

Cancer Solid Tumor, Adult Refractory Cancer Recurrent Cancer

Interventions

  • DRUG Nivolumab
  • BIOLOGICAL IMA203 Product
  • BIOLOGICAL IMA203 product- flat dose
  • BIOLOGICAL IMA203CD8 Product
  • DEVICE IMADetect®

Study Locations (18)

Pennsylvania

  • University of Pennsylvania, Perelamn Center for Advanced Medicine - Philadelphia
  • Fox Chase Cancer Center - Philadelphia
  • University of Pittsburgh Medical Center - Pittsburgh

Bavaria

  • Klinikum rechts der Isar der Technischen Universität München - Munich
  • Klinikum rechts der Isar der Technischen Universität München - Munich
  • Universitätsklinikum Würzburg - Würzburg

Other

  • Charité Benjamin Franklin - Klinik für Hämatologie und Onkologie - Berlin
  • Universitätsklinikum Hamburg-Eppendorf - Hamburg

California

  • Stanford Cancer Institute - Stanford

Florida

  • University of Miami Hospital and Clinics - Miami

Illinois

  • University of Chicago Medical Center - Chicago

Massachusetts

  • Massachusetts General Hospital - Boston

Ohio

  • Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run - Columbus

Trial Details

FieldValue
Enrollment Target 375 participants
Start Date 2019-05-14
Est. Completion 2032-06
Phase Phase 1

Sponsor

Immatics US

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03686124

The ClinicalTrials.gov registry entry for NCT03686124 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,490-participant average among 615 other Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Immatics US, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.

NCT03686124 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Pennsylvania, Bavaria, Other.

Frequently Asked Questions

What is clinical trial NCT03686124 about?

NCT03686124 is a clinical study titled "ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors". The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).

What is the current status of trial NCT03686124?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 375 participants. The study started on 2019-05-14. Estimated completion is 2032-06.

What conditions does trial NCT03686124 study?

This clinical trial studies the following conditions: Cancer, Solid Tumor, Adult, Refractory Cancer, Recurrent Cancer.

What interventions are being tested in trial NCT03686124?

The interventions under investigation include: Nivolumab (DRUG), IMA203 Product (BIOLOGICAL), IMA203 product- flat dose (BIOLOGICAL), IMA203CD8 Product (BIOLOGICAL), IMADetect® (DEVICE).

Who is sponsoring clinical trial NCT03686124?

This trial is sponsored by Immatics US, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03686124 being conducted?

This trial has 18 study locations across California, Florida, Illinois, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Solid Tumor, Adult

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.